Novartis sells $11 billion bonds to fund avidity acquisition

In October, Novartis agreed to acquire Avidity to enhance its focus on innovative drugs in heart, kidney, metabolic, immunology, neuroscience, and oncology

Source: Bloomberg

Continue reading...